Immunology

Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.

Roche agrees $1bn deal with Dualitas for bispecific antibody research

Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up to $1bn, aiming to discover and develop bispecific antibodies for immunology and inflammation (I&I) diseases.

Alfasigma signs agreement to acquire Nordic Group

Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach in Europe, Canada, and Japan.

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China.

Odyssey Therapeutics raises $213m via Series D

Odyssey Therapeutics has closed a $213m Series D financing round, aimed at advancing its portfolio of clinical and preclinical medicines for autoimmune and inflammatory diseases.

Insignis Therapeutics’ IN-001 clinical programme receives positive FDA response

Insignis Therapeutics has received a positive response from the US Food and Drug Administration (FDA) on IN-001 clinical programme for needle-free anaphylaxis treatment.

Astria Therapeutics’ navenibart gains orphan medicinal status from EC

Astria Therapeutics received the European Commission's orphan medicinal product designation (OMPD) for navenibart (STAR-0215) to treat hereditary angioedema (HAE).

Johnson & Johnson seeks FDA approval for generalised myasthenia gravis therapy

Johnson & Johnson has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of nipocalimab, aimed at treating individuals with generalied myasthenia gravis (gMG).